Is there a role for topical antiseptics in the treatment of gonorrhoea?

Miari, Victoria F; Ison, Catherine

doi:10.1136/sextrans-2016-053028

Cited by 5 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the primary function of N-9 is to prevent pregnancy, it is an effective barrier against STDs, including gonorrhea, chlamydia1 infection candidiasis, syphilis, genital herpes, trichomoniasis, and the acquired immunodeficiency syndrome [100][101][102]. However, because of the strong surfactant action of N-9, it often disrupts the vaginal mucosa [103] and targets other cells in the vagina, such as the cervicovaginal epithelia that are essential for maintaining a natural barrier to pathogen invasion, especially HIV [104,105].…”

Section: Bactericides/surfactantmentioning

confidence: 99%

Vaginal Administration of Contraceptives

et al. 2020

View full text Add to dashboard Cite

While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well-established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.

show abstract

Section: Bactericides/surfactantmentioning

confidence: 99%

Vaginal Administration of Contraceptives

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interest in this strategy has resurged in the face of waning efficacy of antibacterial agents. 12 Prophylactic vaginal microbicides have been proposed, 13 although these have not thus far succeeded in clinical trials. 14 A topical antigonorrheal agent may be particularly suited to the challenge of clearing oropharyngeal gonorrhea, as it would circumvent pharmacokinetic challenges of targeting the oropharynx.…”

Section: Introductionmentioning

confidence: 99%

Identification of bile acid and fatty acid species as candidate rapidly bactericidal agents for topical treatment of gonorrhoea

Palace

Fryling

Liu

et al. 2021

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Background Novel therapeutic strategies are urgently needed for Neisseria gonorrhoeae, given its increasing antimicrobial resistance. Treatment of oropharyngeal N. gonorrhoeae infections has proven particularly challenging, with most reported treatment failures of the first-line drug ceftriaxone occurring at this site and lower cure rates in recent trials of new antibiotics reported for oropharyngeal infections compared with other sites of infection. However, the accessibility of the oropharynx to topical therapeutics provides an opportunity for intervention. Local delivery of a therapeutic at a high concentration would enable the use of non-traditional antimicrobial candidates, including biological molecules that exploit underlying chemical sensitivities of N. gonorrhoeae but lack the potency or pharmacokinetic profiles required for effective systemic administration. Methods Two classes of molecules that are thought to limit gonococcal viability in vivo, bile acids and short- and medium-chain fatty acids, were examined for rapid bactericidal activity. Results The bile acids deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA), but not other bile acid species, exerted extremely rapid bactericidal properties against N. gonorrhoeae, reducing viability more than 100 000-fold after 1 min. The short-chain fatty acids formic acid and hexanoic acid shared this rapid bactericidal activity. All four molecules are effective against a phylogenetically diverse panel of N. gonorrhoeae strains, including clinical isolates with upregulated efflux pumps and resistance alleles to the most widely used classes of existing antimicrobials. DCA and CDCA are both approved therapeutics for non-infectious indications and are well-tolerated by cultured epithelial cells. Conclusions DCA and CDCA are attractive candidates for further development as anti-gonococcal agents.

show abstract

“…The threat of multidrug-resistant Neisseria gonorrhoeae (Ng) has motivated the search for alternative, antibiotic-sparing treatment options against this pathogen. The oropharynx gained particular interest as the source of emergence and spreading of resistant Ng due to factors such as poor antimicrobial penetration into the pharyngeal mucosa 1–3 . As a consequence, several authors have proposed that antiseptic mouthwashes may be used to prevent or treat oropharyngeal gonorrhea 1,4,5 …”

mentioning

confidence: 99%

“…The oropharynx gained particular interest as the source of emergence and spreading of resistant Ng due to factors such as poor antimicrobial penetration into the pharyngeal mucosa 1–3 . As a consequence, several authors have proposed that antiseptic mouthwashes may be used to prevent or treat oropharyngeal gonorrhea 1,4,5 …”

mentioning

confidence: 99%